Chan Henry Lee Sells 422 Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 422 shares of BeOne Medicines stock in a transaction on Monday, June 16th. The stock was sold at an average price of $266.50, for a total value of $112,463.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Chan Henry Lee also recently made the following trade(s):

• On Friday, June 6th, Chan Henry Lee sold 700 shares of BeOne Medicines stock. The stock was sold at an average price of $256.11, for a total value of $179,277.00.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $252.78 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The stock has a market capitalization of $27.69 billion, a price-to-earnings ratio of -67.95 and a beta of 0.30. The stock’s 50-day simple moving average is $245.25. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $141.31 and a 1 year high of $287.88.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $1.93. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. Analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on ONC. Royal Bank Of Canada reduced their price objective on shares of BeOne Medicines from $312.00 to $311.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. TD Securities restated a “buy” rating and issued a $334.00 price objective on shares of BeOne Medicines in a report on Thursday, April 24th. Sanford C. Bernstein set a $259.00 price objective on shares of BeOne Medicines in a report on Thursday, March 13th. Bank of America upgraded shares of BeOne Medicines from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $207.00 to $320.00 in a report on Monday, March 3rd. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.